Clinical Trial

Microbiome in Cancer Patients With High Dose Chemotherapy With Stem Cell Transplantation

Study acronym: SCTMICROBIOM
Recruiting
View on ClinicalTrials.gov →
Record status
This record was last updated May 29, 2025 (before its estimated December 2025 completion). Its status may not reflect the trial's current state.
Summary
Numerous in vitro and animal studies as well as growing number of clinical studies support the important role of microbiome in carcinogenesis and cancer treatment. Detection of changes in patients´ microbiome following hematopoietic cell transplantation/CAR-T cell therapy and correlations with adverse transplant outcomes, mainly infectious complications, acute and chronic GvHD, disease recurrence etc. could serve as predictive markers of immune recovery and treatment response.
Protocol Amendment History 6 amendments
This ClinicalTrials.gov record has been amended 6 times since 2020-12-30; most recent amendment 2025-05-22.
Status change: Not Yet Recruiting → Recruiting 2021-03-02
Trial Details
NCT Number NCT04691284
Lead Sponsor National Cancer Institute, Slovakia
Collaborators: Slovak Academy of Sciences
Conditions Hematologic Neoplasms
Enrollment 100 participants
Start Date 2021-03-01
Primary Completion 2025-12 (estimated)
Study Completion 2026-12 (estimated)
Updated on ClinicalTrials.gov 2025-05-29